Related Experiment Video
Updated: Aug 16, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
The use of medications for inflammatory bowel disease during pregnancy and nursing
1Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
Insights
This review examines the safety of medications for pregnant women with inflammatory bowel disease (IBD). It assesses risks to the fetus and pregnancy course, aiding treatment decisions for ulcerative colitis and Crohn
Area of Science:
- Gastroenterology and Obstetrics
- Reproductive Medicine
- Clinical Pharmacology
Background:
- Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, predominantly affects young adults aged 15-25.
- Current IBD treatments focus on managing the heightened inflammatory response in the intestinal mucosa.
- The peak age for IBD onset overlaps with the typical childbearing years, creating complex clinical scenarios for pregnant patients.
Purpose of the Study:
- To review existing safety data on medications used for inflammatory bowel disease during pregnancy.
- To evaluate the benefits of maternal IBD treatment against potential risks to the fetus and pregnancy.
- To provide evidence-based guidance for managing pregnant women with IBD.
Main Methods:
- Systematic review of current literature on IBD medications in pregnancy.
- Analysis of safety data regarding fetal outcomes and pregnancy course.
- Evaluation of therapeutic benefits versus potential teratogenic or adverse effects.
Main Results:
- The review synthesizes available safety information on various IBD medications.
- Data highlights the importance of individualized risk-benefit assessments for each medication.
- Specific drug safety profiles during pregnancy are discussed.
Conclusions:
- Managing IBD in pregnant patients requires careful consideration of medication safety.
- Weighing maternal health benefits against fetal risks is crucial for optimal treatment strategies.
- Further research is needed to fully elucidate the long-term effects of IBD medications during gestation.
Abstract:
Inflammatory bowel disease includes two primary disorders, ulcerative colitis and Crohn's disease. These diseases mainly affect young adults, with a peak occurrence between 15 and 25 years of age. The causes of these diseases are largely unknown, with current treatments targeted against the heightened inflammatory response witnessed in the intestinal mucosa of both conditions. With the peak age ranges for pregnancy and inflammatory bowel disease overlapping, it is important to weigh the benefits of treating a mother during pregnancy against the potential risks to the fetus and the course of the pregnancy. This review examines the current safety data on medications used in women with inflammatory bowel disease during pregnancy.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
